等待开盘 04-01 09:30:00 美东时间
+0.335
+2.31%
PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded
03-26 02:09
PureTech Health ( ($GB:PRTC) ) has issued an announcement. PureTech Health’s fo...
03-26 02:07
CAMP4 Therapeutics announced the appointment of Michael MacLean to its Board of Directors. With over 35 years of financial and operational leadership in biotechnology, MacLean brings extensive experience in growing innovative biotech companies. His expertise will support CAMP4 as it advances its CMP-002 program toward a Phase 1/2 clinical trial for SYNGAP1-related disorder, for which there are currently no approved treatments. MacLean previously ...
03-24 11:00
PureTech Health to Present at Leerink Partners Global Healthcare Conference PureTech Health plc said CEO Robert Lyne and Co-founder and President Eric Elenko will take part in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026, at 11:20am EDT, with a we
02-25 15:00
PureTech Health ( ($GB:PRTC) ) has issued an announcement. PureTech Health’s Fo...
02-20 01:17
PureTech Health plc (PRTC) has appointed Robert Lyne as Chief Executive Officer and as a member of the Board of Directors, effective immediately. Lyne has served as interim CEO since July 2025 and joi...
2025-12-18 18:18
PureTech Health ( ($GB:PRTC) ) has provided an announcement. PureTech Health an...
2025-12-11 01:48
** Shares of PureTech Health PRTC.L up 4.1% at 127p ** Stock among top gainers on FTSE Small Cap index .FTSC, which is flat ** Co announces successful End-of-Phase 2 Meeting with FDA for Deupirfenidon...
2025-12-08 16:28
LYT-200 demonstrated favorable tolerability and strong efficacy in a heavily pretreated population, both in combination with standard of care and as a monotherapy, supporting advancement toward a potentially
2025-12-06 02:02
PureTech Health plc has announced initial topline results from a Phase 1b clinical trial conducted by its Founded Entity, Gallop Oncology, evaluating LYT-200, a first-in-class anti-galectin-9 monoclon...
2025-12-06 02:00